US2003092644A1PendingUtilityA1

Treatment of viral infections using levovirin

44
Priority: Dec 23, 1999Filed: Dec 15, 2000Published: May 15, 2003
Est. expiryDec 23, 2019(expired)· nominal 20-yr term from priority
Inventors:Keiko AbeNoboru YanagitaTakumi YoshidaNorifumi Zushi
A61P 31/14A61P 31/18A61P 31/12A61P 37/02C07H 19/056A61K 31/7056C07H 19/044A61K 31/4196
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A 1-(β-L-ribofuranosyl)-1,2,4-triazole-3-carboxamide is administered in a method of treatment of a viral infection in a patient, including IV infection, HCV infection, or BHV infection.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treatment of a viral infection in a patient comprising: 
 administering a compound according to structure 1;    wherein structure 1 is                          
     
     
         2 . The method of  claim 1  wherein the viral infection is selected from the group consisting of a HIV infection, a HCV infection, and a HBV infection.  
     
     
         3 . The method of  claim 1  wherein the step of administering increases a Th1 response relative to a Th2 response in the patient.  
     
     
         4 . The method of  claim 3  wherein the Th1 response increases.  
     
     
         5 . The method of  claim 4  wherein the increase in the Th1 response comprises a mean peak increase over an activated control level in IL-2 of at least 70% (by weight).  
     
     
         6 . The method of  claim 4  wherein the increase in the Th1 response comprises a mean peak increase over an activated control level in IFN-γ of at least 20% (by weight).  
     
     
         7 . The method of  claim 4  wherein the increase in the Th1 response comprises a mean peak increase over an activated control level in TNF-α of at least 50% (by weight).  
     
     
         8 . The method of  claim 4  wherein the increase in the Th1 response comprises a mean peak increase over an activated control level in IL-2, IFN-γ, and TNF-α of 42% (by weight), 125% (by weight), and 72% (by weight), respectively.  
     
     
         9 . The method of  claim 1  wherein the step of administering comprises in vivo administration.  
     
     
         10 . The method of  claim 1  wherein the step of administering comprises oral administration.  
     
     
         11 . The method of  claim 1  wherein the step of administering comprises injection.  
     
     
         12 . The method of  claim 1  wherein the step of administering comprises administering the compound in a dose between 0.1 mg per kg of body weight of the patient and 1.0 mg per kg of body weight of the patient.  
     
     
         13 . A modulator of an immune response according to structure 1:

Join the waitlist — get patent alerts

Track US2003092644A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.